Clinical Cancer esearch ing , Diagnosis , Prognosis omparison of PAM 50 Intrinsic Subtyping with unohistochemistry and Clinical Prognostic Factors in oxifen-Treated Estrogen Receptor – Positive R ast Cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

  2010cited by this paper
• Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009influential reference
• Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2009cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

  2008cited by this paper
• New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up

  2008cited by this paper
• Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

  2008cited by this paper
• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

  2007cited by this paper
• Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.

  2007cited by this paper
• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  2007cited by this paper
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

  2006cited by this paper
• Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

  2006influential reference
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

  2005cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper
• Cox Analysis of Survival Data with Non‐Proportional Hazard Functions

  1992cited by this paper

• The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer

  2023cites this paper
• Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?

  2023cites this paper
• TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.

  2023cites this paper
• Deconvolution of cancer cell states by the XDec-SM method

  2023cites this paper
• Identification of the prognostic value of Th1/Th2 ratio and a novel prognostic signature in basal-like breast cancer

  2023cites this paper
• Learning vector quantized representation for cancer subtypes identification

  2023cites this paper
• Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions

  2023cites this paper
• An MRI-based Radiomics Approach to Improve Breast Cancer Histological Grading.

  2023cites this paper
• Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.

  2023cites this paper
• Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma

  2023cites this paper
• PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study

  2023cites this paper
• No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country

  2023cites this paper
• KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy

  2023cites this paper
• Cancer Subtyping by Improved Transcriptomic Features Using Vector Quantized Variational Autoencoder

  2022cites this paper
• Utility of Genomic Platforms in Treatment Decisions in Axilla-Positive Breast Cancer.

  2022cites this paper
• Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

  2022cites this paper
• ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

  2022cites this paper
• HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

  2022cites this paper
• Gene selection using pyramid gravitational search algorithm

  2022cites this paper
• Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry

  2022cites this paper
• Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors

  2022cites this paper
• The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?

  2022cites this paper
• Deep neural networks with knockoff features identify nonlinear causal relations and estimate effect sizes in complex biological systems

  2022cites this paper
• The CpG Island-Binding Protein SAMD1 Contributes to an Unfavorable Gene Signature in HepG2 Hepatocellular Carcinoma Cells

  2022cites this paper
• A text-based computational framework for patient -specific modeling for classification of cancers

  2022cites this paper
• A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers

  2022cites this paper
• circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer

  2022cites this paper
• Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study

  2022cites this paper
• XDec Simplex Map of Breast Cancer Cell States Enables Precise Modeling and Targeting of Breast Cancer

  2022influential citation
• Firmas génicas en el cáncer de mama

  2022cites this paper
• Predicting hormone receptors and PAM50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique

  2022cites this paper
• Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin

  2022cites this paper
• Development and testing of a polygenic risk score for breast cancer aggressiveness

  2022cites this paper
• Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?

  2022cites this paper
• PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

  2022cites this paper
• Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

  2022cites this paper
• ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers

  2022cites this paper
• A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA

  2022cites this paper
• The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients

  2022influential citation
• VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models

  2022cites this paper
• Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

  2021cites this paper
• Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer.

  2021cites this paper
• A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery

  2021cites this paper
• Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations

  2021cites this paper
• Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC)

  2021cites this paper
• Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

  2021cites this paper
• Screening and identification of haptoglobin showing its important role in pathophysiological process of gallbladder carcinoma.

  2021cites this paper
• Genomic Assays in Node Positive Breast Cancer Patients: A Review

  2021cites this paper
• ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes

  2021cites this paper
• Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

  2021cites this paper
• Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

  2021cites this paper
• Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

  2021cites this paper
• Clinical and morphological factors associated with two groups of concordant breast cancer immunophenotypes: a cross-sectional study of 24-year historical series

  2021cites this paper
• Oncotype DX and Prosigna in breast cancer patients: A comparison study.

  2021cites this paper
• Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter

  2021cites this paper
• Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

  2021cites this paper
• Integrative multiomics-histopathology analysis for breast cancer classification

  2021cites this paper
• Clinicopathological correlation of stem cell markers expression in oral squamous cell carcinoma; relation to patients` outcome

  2021cites this paper
• Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

  2021cites this paper
• Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms

  2021cites this paper
• Molecular genetic predictors of metastatic lesions of regional lymph nodes in patients with breast cancer

  2021cites this paper
• Gene expression profiles of breast cancer metastasis according to organ site

  2021cites this paper
• Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.

  2021cites this paper
• Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer

  2021cites this paper
• Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer

  2021cites this paper
• Comprehensive Analysis of Splicing Factor and Alternative Splicing Event to Construct Subtype-Specific Prognosis-Predicting Models for Breast Cancer

  2021cites this paper
• Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer.

  2021cites this paper
• A single-cell and spatially resolved atlas of human breast cancers

  2021cites this paper
• Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer

  2021cites this paper
• Competing risks of mortality by PAM50 intrinsic subtype of British Columbia tamoxifen-treated cohort of post-menopausal breast cancer patients

  2021cites this paper
• Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer

  2021cites this paper
• CPT1A and fatty acid β-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer

  2021cites this paper
• iGlioSub: an integrative transcriptomic and epigenomic classifier for glioblastoma molecular subtypes

  2021cites this paper
• Advancement of prognostic models in breast cancer: a narrative review.

  2021cites this paper
• Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes

  2021cites this paper
• Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  2020cites this paper
• Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions

  2020cites this paper
• Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review

  2020cites this paper
• Genomics and Bioinformatics in Biological Discovery and Pharmaceutical Development

  2020cites this paper
• Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.

  2020cites this paper
• Mitochondrial DNA Mutation Analysis in Breast Cancer: Shifting From Germline Heteroplasmy Toward Homoplasmy in Tumors

  2020cites this paper
• Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications

  2020cites this paper
• Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer

  2020cites this paper
• An Ultra-Fast Method for Clustering of Big Genomic Data

  2020cites this paper
• Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features

  2020cites this paper
• Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium

  2020cites this paper
• A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer

  2020cites this paper
• A tetraprenylated benzophenone 7-epiclusianone induces cell cycle arrest at G1/S transition by modulating critical regulators of cell cycle in breast cancer cell lines.

  2020cites this paper
• Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions

  2020cites this paper
• Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5

  2020cites this paper
• Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer

  2020cites this paper
• Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort

  2020cites this paper
• Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

  2020cites this paper
• Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers

  2020cites this paper
• Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer

  2020cites this paper
• Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients

  2020cites this paper
• Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

  2020cites this paper
• Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype

  2020cites this paper
• SPECIAL SERIES: LOCOREGIONAL MANAGEMENT OF BREAST CANCER

  2020cites this paper
• Identification of specific microRNA-messenger RNA regulation pairs in four subtypes of breast cancer.

  2020cites this paper